Access cutting-edge chronic lymphocytic leukemia treatment through this clinical trial at a research site in New Orleans. Study-provided care at no cost to qualified participants.
Access chronic lymphocytic leukemia specialists in New Orleans at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chronic lymphocytic leukemia treatment provided free
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.
Sponsor: Loxo Oncology, Inc.
Check if you qualify for this chronic lymphocytic leukemia clinical trial in New Orleans, LA
If you're searching for chronic lymphocytic leukemia treatment options in New Orleans, LA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Orleans research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic lymphocytic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.